Solara Active Pharma Sciences

Chennai, India Founded: 2018 • Age: 8 yrs Listed
APIs and intermediates are manufactured for therapeutic categories.
Request Access
Report Incorrect Data
Page last updated

About Solara Active Pharma Sciences

Solara Active Pharma Sciences is a publicly listed company based in Chennai (India) founded in 2018. APIs and intermediates are manufactured for therapeutic categories. The company has 1,209 employees. Its chief executive, as recorded, is Poorvank Purohit. Its Indian entity Solara Active Pharma Sciences Limited reported revenue of ₹1,375 Cr. Solara Active Pharma Sciences offers products and services including Active Pharmaceutical Ingredients and CRAMS Services. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.

Company details

Solara Active Pharma Sciences was founded in 2018 and is based in Chennai, India. Active pharmaceutical ingredients and intermediates for various therapeutic categories are produced by the company. Manufacturing and research development sites are maintained in-house. Facilities are certified under ISO 14001 for environmental management and GMP for quality standards. Operations focus on the pharmaceutical sector with an emphasis on production processes.

  • Headquarters Chennai, India
  • Employees 1,209
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website solara.co.in
  • Social LinkedIn
  • Legal Name Solara Active Pharma Sciences Ltd.
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹3,145 Cr

    SOLARA · NSE

  • Share Price
    ₹648.05

    -0.99% today

  • Revenue
    ₹1,369 Cr

    FY 2025-26 · +6.6% YoY

  • EBITDA
    ₹181 Cr

    Margin 13.2%

  • Net Profit
    −₹1.52 Cr

    FY 2025-26 · -381.5% YoY

  • P/E (TTM)
    67.1x

    P/B 2.2x

  • Debt / Equity
    0.63

    Interest cover 116.7x

  • Employee Count
    1,209

Products & Services of Solara Active Pharma Sciences

Solara Active Pharma Sciences offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients and CRAMS Services.

Active Pharmaceutical Ingredients
Pharmaceutical Products

Manufacturing of active pharmaceutical ingredients is conducted with a focus on quality and innovation to meet customer needs.

CRAMS Services
Research Services

Contract research and manufacturing services are provided, including new product filings and support for market extensions.

Board of directors of Solara Active Pharma Sciences Limited (Solara Active Pharma Sciences)

Solara Active Pharma Sciences Limited is the primary company behind Solara Active Pharma Sciences. The board of Solara Active Pharma Sciences Limited currently have 8 directors; the longest-serving is Ramakrishnan Rajagopal, appointed in 2018. 22 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramakrishnan Rajagopal
DIN 00161542
Director11 Apr 20188 yrs 7 moSolara Active Pharma Sciences Limited
Kausalya Santhanam
DIN 06999168
Director11 Apr 20188 yrs 7 moSolara Active Pharma Sciences Limited
Arun Kumar Pillai
DIN 00084845
Director04 Aug 20215 yrs 3 moSolara Active Pharma Sciences Limited
Rajendra Kumar Srivastava
DIN 07500741
Director14 Nov 20232 yrs 11 moSolara Active Pharma Sciences Limited
Rajiv Vijay Nabar
DIN 10383397
Director14 Nov 20232 yrs 11 moSolara Active Pharma Sciences Limited
Manish Gupta
DIN 06805265
Director22 Jul 20242 yrs 3 moSolara Active Pharma Sciences Limited
Sandeep Shashikantha Rao
DIN 10838251
Managing Director21 Feb 20251 yr 8 moSolara Active Pharma Sciences Limited
Sanjeevi Mohanraj
DIN 08420411
Whole-Time Director01 Jan 202610 moSolara Active Pharma Sciences Limited

People of Solara Active Pharma Sciences

35 people are tracked at Solara Active Pharma Sciences (18 in leadership, 17 in team); the tracked headcount is 1,209.

NameRoleGroup
Poorvank Purohit
CEO & Managing DirectorLeadership
Ameet Kumar
Corporate HR HeadLeadership
Carolina Campos
Head Of Sales - LatamLeadership
Surendrakumar Yadav
Deputy General Manager OperationsLeadership
Karthik Gopu
Head - Projects ManagementLeadership
Sundara Moorthy V
Chief Quality OfficerLeadership
Dr. Hero Velladurai
Chief Scientific OfficerLeadership
Sankar Arjunan
General Manager, R&d ( Api- Generics )Leadership
Kannan N S
Associate Vice PresidentLeadership
Seenuvasan Ambalavanan
Deputy General Manager - Head Technical Service Across Solara GroupLeadership
Ganesh Mukundan
Global Head - Pain Management GroupLeadership
Amrita Gore
Director- API Business Development North America And MexicoLeadership
Mohan M
Chief Operating OfficerLeadership
Ammar Shabbir Ali Taj
Deputy General Manager - Sales & Business Development (europe)Leadership
Mohan Muthunarayanan
Executive Director & COOLeadership
Manonmani Augustus
General ManagerLeadership
Muthuraju S
Regional Sales Head (us, Eu, Canada, Mexico, Russia / Cis) - Pain Management GroupLeadership
Sridharan V
Deputy General ManagerLeadership
Rajesh Waran
Quality Assurance OfficerTeam
Satya Prakash N.
Assistant ManagerTeam

15 more people are available in the full profile.

Premium access

Complete people profiles for Solara Active Pharma Sciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Solara Active Pharma Sciences

Solara Active Pharma Sciences is a publicly listed company on the NSE with ticker symbol SOLARA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date27 Jun 2024
  • Listed onBSE: 890202
  • Listed entitySolara Active Pharma Sciences Ltd.
  • Exchange sectorHealth technology
  • ISININE624Z01016
  • Share price₹646.75 (-1.5% on the day) · 2026-10-14
  • Market capitalisation₹3,157 Cr
  • Price to earnings407.7
  • EPS (diluted, trailing year)₹-0.68
  • Volume (last session)49,155

Financials of Solara Active Pharma Sciences

Exchange-reported figures of Solara Active Pharma Sciences Limited, the listed company behind Solara Active Pharma Sciences (NSE: SOLARA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,369 Cr
+6.6% YoY
EBITDA
₹181 Cr
-12.3% YoY
Profit After Tax
−₹1.52 Cr
-381.5% YoY
Net Worth
₹1,253 Cr
+14.5% YoY
Total Assets
₹1,996 Cr
+2.2% YoY
Total Debt
₹687 Cr
-13.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA181206(285)13476.48386259
EBITDA margin+13.2%+16.1%-22.1%+9.3%+6.0%+23.9%+19.6%
Profit before tax(7.41)0.54(488)(44.82)(91.10)222115
Net profit(1.52)0.54(408)(21.73)(53.90)220115
Net profit margin-0.1%+0.0%-31.7%-1.5%-4.3%+13.6%+8.7%
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
Balance sheet
Total assets1,9961,9522,0022,5652,6252,2791,888
Net worth1,2531,0949341,5001,5251,5891,086
Total debt6877961,0121,0131,037621722
Cash & bank50.344.118.608.8947.2519956.78
Net working capital518449452853919723419
Cash flow
Cash from operations153213109156(242)155242
Cash from investing(98.83)(36.83)(3.51)(81.14)(243)(106)(359)
Cash from financing(53.55)(180)(106)(113)33492.4996.98
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.542.695.550.000.490.985.951.49
EBITDA72.3461.9757.6630.5934.7357.0245.3757.68
EBITDA margin+17.3%+16.2%+14.9%+8.8%+11.1%+17.9%+16.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest17.7821.6427.5722.4520.8323.9029.1226.54
Profit before tax28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
Tax0.000.000.000.000.000.000.000.00
Net profit28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
EPS (₹)5.923.522.20(3.98)(2.36)2.46(0.93)2.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA181204(285)13476.86385257
EBITDA margin+13.2%+15.9%-22.1%+9.3%+6.1%+23.8%+19.4%
Profit before tax(7.24)(1.08)(488)(44.78)(91.66)221112
Net profit(1.35)(1.08)(408)(21.76)(54.30)219113
Net profit margin-0.1%-0.1%-31.7%-1.5%-4.3%+13.6%+8.5%
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
Balance sheet
Total assets1,9461,9512,0032,5652,6252,2791,889
Net worth1,2551,0969371,5031,5271,5931,091
Total debt6377961,0121,0131,037621722
Cash & bank4.163.978.488.7147.1419856.58
Net working capital478455447861927727424
Cash flow
Cash from operations153213111156(242)154242
Cash from investing(50.14)(36.83)(4.66)(81.13)(243)(105)(359)
Cash from financing(103)(180)(107)(113)33492.5097.01
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.231.925.280.000.490.985.951.49
Total expenses345320330318279262230243
EBITDA72.3862.0157.5530.6034.7557.0342.5957.69
EBITDA margin+17.3%+16.3%+14.9%+8.8%+11.1%+17.9%+15.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest16.3620.2327.0622.4520.8323.9029.1226.54
Profit before tax29.6116.999.73(17.42)(10.08)10.53(4.88)8.10
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.542.695.550.000.490.985.951.49
EBITDA72.3461.9757.6630.5934.7357.0245.3757.68
EBITDA margin+17.3%+16.2%+14.9%+8.8%+11.1%+17.9%+16.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest17.7821.6427.5722.4520.8323.9029.1226.54
Profit before tax28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
Tax0.000.000.000.000.000.000.000.00
Net profit28.4616.319.60(17.43)(10.10)10.52(2.10)8.09
EPS (₹)5.923.522.20(3.98)(2.36)2.46(0.93)2.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
Other income6.168.325.3722.5520.0228.7727.52
Total expenses1,1881,0771,5741,3101,1921,2311,062
Employee cost224215247229236229204
EBITDA181206(285)13476.48386259
EBITDA margin+13.2%+16.1%-22.1%+9.3%+6.0%+23.9%+19.6%
Depreciation99.6899.2510311111210994.16
Interest94.7511510590.0675.2884.4877.89
Profit before tax(7.41)0.54(488)(44.82)(91.10)222115
Tax0.000.0078.54(22.57)(32.81)0.150.39
Net profit(1.52)0.54(408)(21.73)(53.90)220115
Net profit margin-0.1%+0.0%-31.7%-1.5%-4.3%+13.6%+8.7%
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.5140.2536.0036.0036.0035.9326.85
Reserves & surplus1,2081,0548981,4641,4891,553963
Shareholders' funds (net worth)1,2531,0949341,5001,5251,5891,086
Minority interest2.672.672.672.242.314.244.29
Secured loans6657399081,0011,025607707
Unsecured loans22.0257.5210311.7012.8013.8215.17
Total debt6877961,0121,0131,037621722
Total liabilities1,9961,9522,0022,5652,6252,2791,888
Assets
Gross block2,0381,8991,8791,8951,7791,7021,611
Net block1,2381,1931,2681,3641,3561,3821,397
Capital work in progress20528025623823987.9840.47
Investments4.621.701.701.700.420.420.32
Inventories318318360558576295280
Sundry debtors439327349537490484227
Cash & bank balances50.344.118.608.8947.2519956.78
Loans & advances48.1780.1583.9383.5712780.25109
Total current assets8557298011,1881,2391,058672
Total current liabilities337280349335320335253
Net working capital518449452853919723419
Total assets1,9961,9522,0022,5652,6252,2791,888
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.958.448.7346.3819856.0475.72
Net cash from operating activities153213109156(242)155242
Net cash from investing activities(98.83)(36.83)(3.51)(81.14)(243)(106)(359)
Net cash from financing activities(53.55)(180)(106)(113)33492.4996.98
Net change in cash0.53(4.49)(0.29)(37.65)(151)142(19.68)
Closing cash50.344.118.608.8947.2519956.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA growth-12.3%+172.3%-313.1%+75.1%-80.2%+48.7%-
PBT growth-+9998.0%-989.7%+50.8%-+92.8%+91.6%
Net income growth-381.5%+100.1%-1778.1%+59.7%-124.5%+91.3%-
Revenue CAGR (3Y)-1.8%+0.4%-7.3%+3.0%-2.9%+45.9%-
EBITDA CAGR (3Y)+10.6%+39.2%--19.8%-28.9%+89.3%-
Profitability & leverage
Net income margin-0.5%+0.0%-44.0%-1.5%-4.6%+13.7%+8.7%
Return on capital employed0.0%+5.4%0.0%+1.7%-0.7%+14.7%+11.1%
Return on net worth0.0%+0.1%0.0%-1.5%-3.7%+16.6%+11.2%
Debt / equity0.630.890.830.680.530.500.62
Long-term debt / equity0.110.120.150.180.150.150.23
Interest cover116.72107.27-27.04396.91-210.0430.4847.13
Efficiency & per share
Fixed asset turnover0.700.680.680.790.730.980.90
Inventory turnover4.313.792.812.552.915.635.35
Debtors turnover3.583.802.912.812.614.555.13
EPS (₹)(1.66)0.13(157.61)(6.16)(16.15)61.6242.69
Dividend per share (₹)0.000.000.003.000.007.002.00
Book value per share (₹)281.48271.86259.42416.73423.57442.12368.69
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue417382387349314319273300
Revenue growth (YoY)+33.1%+19.6%+41.9%+16.2%-9.6%-12.2%--
Other income0.231.925.280.000.490.985.951.49
Total expenses345320330318279262230243
EBITDA72.3862.0157.5530.6034.7557.0342.5957.69
EBITDA margin+17.3%+16.3%+14.9%+8.8%+11.1%+17.9%+15.6%+19.2%
Depreciation26.6426.7126.0425.5724.4923.5824.3024.54
Interest16.3620.2327.0622.4520.8323.9029.1226.54
Profit before tax29.6116.999.73(17.42)(10.08)10.53(4.88)8.10
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3691,2841,2891,4441,2681,6171,322
Revenue growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
Other income5.899.145.3722.1418.7628.4127.51
Total expenses1,1881,0801,5741,3101,1911,2321,065
Employee cost224215247228234228202
EBITDA181204(285)13476.86385257
EBITDA margin+13.2%+15.9%-22.1%+9.3%+6.1%+23.8%+19.4%
Depreciation99.6899.2510311111210893.67
Interest94.2411510690.0675.2784.4777.88
Profit before tax(7.24)(1.08)(488)(44.78)(91.66)221112
Tax0.000.0078.54(22.57)(33.10)0.000.00
Net profit(1.35)(1.08)(408)(21.76)(54.30)219113
Net profit margin-0.1%-0.1%-31.7%-1.5%-4.3%+13.6%+8.5%
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital44.5140.2536.0036.0036.0035.9326.85
Reserves & surplus1,2111,0569011,4671,4911,557968
Shareholders' funds (net worth)1,2551,0969371,5031,5271,5931,091
Secured loans6157399081,0011,025607707
Unsecured loans22.0257.5210311.7012.8013.8215.17
Total debt6377961,0121,0131,037621722
Total liabilities1,9461,9512,0032,5652,6252,2791,889
Assets
Gross block2,0311,8921,9331,8711,7641,6781,587
Net block1,2311,1871,2611,3421,3341,3591,374
Capital work in progress20528025623823987.7240.21
Investments1.631.7014.2516.0514.7718.1318.03
Inventories318318360558576295280
Sundry debtors439327351540490484230
Cash & bank balances4.163.978.488.7147.1419856.58
Loans & advances47.7980.1671.2584.4212880.83109
Total current assets8097297911,1911,2401,058675
Total current liabilities331274344330312331251
Net working capital478455447861927727424
Total assets1,9461,9512,0032,5652,6252,2791,889
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.818.328.5546.2719855.8475.62
Net cash from operating activities153213111156(242)154242
Net cash from investing activities(50.14)(36.83)(4.66)(81.13)(243)(105)(359)
Net cash from financing activities(103)(180)(107)(113)33492.5097.01
Net change in cash0.19(4.51)(0.23)(37.72)(151)142(19.78)
Closing cash4.163.978.488.7147.1419856.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.6%-0.4%-10.7%+13.8%-21.6%+22.3%-
EBITDA growth-11.3%+171.6%-312.4%+74.4%-80.1%+50.2%-
PBT growth-570.4%+99.8%-990.5%+51.2%-+96.4%+85.4%
Net income growth-25.0%+99.7%-1775.1%+59.9%-124.8%+94.5%-
Revenue CAGR (3Y)-1.8%+0.4%-7.3%+3.0%-2.9%+45.9%-
EBITDA CAGR (3Y)+10.5%+38.4%--19.5%-28.9%+87.3%-
Profitability & leverage
Net income margin-0.5%-0.1%-44.0%-1.5%-4.6%+13.7%+8.5%
Return on capital employed0.0%0.0%0.0%+1.7%-0.7%+14.7%+11.0%
Return on net worth0.0%0.0%0.0%-1.5%-3.8%+16.5%+11.0%
Debt / equity0.610.890.830.680.530.500.61
Long-term debt / equity0.090.120.150.180.150.150.23
Interest cover116.19109.77-27.33389.20-214.1430.4947.82
Efficiency & per share
Fixed asset turnover0.700.670.680.790.740.990.91
Inventory turnover4.313.792.812.552.915.635.35
Debtors turnover3.583.792.892.812.614.535.08
EPS (₹)(1.63)(0.27)(157.46)(6.17)(16.27)61.5041.90
Dividend per share (₹)0.000.000.003.000.007.002.00
Book value per share (₹)282.06272.35260.39417.54424.18443.30370.50

Web traffic of Solara Active Pharma Sciences

The website of Solara Active Pharma Sciences (solara.co.in) receives about 5.9K visits a month.

  • Monthly visits
    5.9K

    ▲ 25% vs previous month

Similar websites

Websites whose visitors overlap most with Solara Active Pharma Sciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Microvista Technologies
microvistatech.com
100%
54.7K#533,664View details
solaratalent.com
solaratalent.com
65%
–

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Solara Active Pharma Sciences (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Solara Active Pharma Sciences

SOLARA: Q2 CONS NET PROFIT 285M RUPEES VS LOSS 101M (YOY)
Exchange Update • 25 days ago
SOLARA: Q2 REVENUE 4.2B RUPEES VS 3.14B (YOY)
Exchange Update • 25 days ago
SOLARA: Q2 EBITDA 771M RUPEES VS 347.3M (YOY); Q2 EBITDA MARGIN 18.25% VS 11.08% (YOY)
Exchange Update • 25 days ago
TPG-backed Solara Active Pharma Sciences draws PE suitors
VCCircle • 2 months ago
TPG-backed Solara Active Pharma Sciences draws PE suitors
VCCircle • 2 months ago
Solara Active Pharma Sciences Says Tax Demand Of 1.62 Billion Rupees Reduced To Nil After Rectification
Reuters • 2 months ago
Solara Active Pharma Gets Rs 162 Crore Tax Demand Reduced to Zero
CNBC-TV18 • 2 months ago
Solara Active Pharma Sciences June-Quarter Consol Net Profit 163.1 Million Rupees
Reuters • 3 months ago
How is TPG faring in its second Indian pharma bet?
VCCircle • 3 months ago
Solara Active Pharma Sciences March-Quarter Consol Net Profit 96 Million Rupees
Reuters • 5 months ago
Premium access

Complete news archive for Solara Active Pharma Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Solara Active Pharma Sciences

Solara Active Pharma Sciences was founded in 2018.

Solara Active Pharma Sciences is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.

Poorvank Purohit is the CEO of Solara Active Pharma Sciences, as recorded in our data.

Solara Active Pharma Sciences has 1,209 employees.

The primary company behind Solara Active Pharma Sciences, Solara Active Pharma Sciences Limited, reported revenue of ₹1,375 Cr for FY 2026, up 7% year on year.

Solara Active Pharma Sciences was founded in 2018 and is based in Chennai, India. Active pharmaceutical ingredients and intermediates for various therapeutic categories are produced by the company. Manufacturing and research development sites are maintained in-house. Facilities are certified under ISO 14001 for environmental management and GMP for quality standards. Operations focus on the pharmaceutical sector with an emphasis on production processes.

Solara Active Pharma Sciences offers Active Pharmaceutical Ingredients and CRAMS Services.

Yes, Solara Active Pharma Sciences is publicly traded on NSE under the ticker symbol SOLARA.

Solara Active Pharma Sciences operates through Solara Active Pharma Sciences Limited.

The legal entities of Solara Active Pharma Sciences currently have 10 directors, including Ramakrishnan Rajagopal, Kausalya Santhanam, Arun Kumar Pillai and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available